Safety Aspects of Bio-Based Nanomaterials

Moving towards a bio-based and circular economy implies a major focus on the responsible and sustainable utilization of bio-resources. The emergence of nanotechnology has opened multiple possibilities, not only in the existing industrial sectors, but also for completely novel applications of nanoscale bio-materials, the commercial exploitation of which has only begun during the last few years. Bio-based materials are often assumed not to be toxic. However, this pre-assumption is not necessarily true. Here, we provide a short overview on health and environmental aspects associated with bio-based nanomaterials, and on the relevant regulatory requirements. We also discuss testing strategies that may be used for screening purposes at pre-commercial stages. Although the tests presently used to reveal hazards are still evolving, regarding modifications required for nanomaterials, their application is needed before the upscaling or commercialization of bio-based nanomaterials, to ensure the market potential of the nanomaterials is not delayed by uncertainties about safety issues.

[1]  綾子 武見,et al.  Globally Harmonized System of Classification and Labelling of Chemicals (GHS) , 2019, Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

[2]  L. Paula,et al.  EU ambition to build the world's leading bioeconomy-Uncertain times demand innovative and sustainable solutions. , 2018, New biotechnology.

[3]  Maria Dusinska,et al.  Immunotoxicity, genotoxicity and epigenetic toxicity of nanomaterials: New strategies for toxicity testing? , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  João Paulo Teixeira,et al.  Nanomaterials Versus Ambient Ultrafine Particles: An Opportunity to Exchange Toxicology Knowledge , 2017, Environmental health perspectives.

[5]  Gary Chinga-Carrasco,et al.  Lignocellulosics as sustainable resources for production of bioplastics – A review , 2017 .

[6]  Helene Stockmann-Juvala,et al.  A theoretical approach for a weighted assessment of the mutagenic potential of nanomaterials , 2017, Nanotoxicology.

[7]  H. Norppa,et al.  Evaluation of the genotoxic potential of different types of nanofibrillated celluloses , 2017 .

[8]  J. Ede,et al.  Establishing the safety of novel bio-based cellulose nanomaterials for commercialization , 2017 .

[9]  M. Strømme,et al.  In vitro biological responses to nanofibrillated cellulose by human dermal, lung and immune cells: surface chemistry aspect , 2017, Particle and Fibre Toxicology.

[10]  R. Vandebriel,et al.  Immunotoxicity Testing of Nanomedicinal Products: Possible Pitfalls in Endotoxin Determination , 2017 .

[11]  C. Endes,et al.  A critical review of the current knowledge regarding the biological impact of nanocellulose , 2016, Journal of Nanobiotechnology.

[12]  Stephen J. Evans,et al.  Critical review of the current and future challenges associated with advanced in vitro systems towards the study of nanoparticle (secondary) genotoxicity , 2016, Mutagenesis.

[13]  G. Chinga-Carrasco,et al.  Producing ultrapure wood cellulose nanofibrils and evaluating the cytotoxicity using human skin cells. , 2016, Carbohydrate polymers.

[14]  Adriele Prina-Mello,et al.  Towards a nanospecific approach for risk assessment. , 2016, Regulatory toxicology and pharmacology : RTP.

[15]  V. Kokol,et al.  Native cellulose nanofibrills induce immune tolerance in vitro by acting on dendritic cells , 2016, Scientific Reports.

[16]  G. V. Van Norman.  Drugs and Devices , 2016, JACC. Basic to translational science.

[17]  Jo Anne Shatkin,et al.  Toward cellulose nanomaterial commercialization: knowledge gap analysis for safety data sheets according to the globally harmonized system , 2016 .

[18]  Wim H de Jong,et al.  A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements , 2016, International journal of nanomedicine.

[19]  Andrew Williams,et al.  Gender differences in murine pulmonary responses elicited by cellulose nanocrystals , 2015, Particle and Fibre Toxicology.

[20]  Jo Anne Shatkin,et al.  Cellulose nanomaterials: life cycle risk assessment, and environmental health and safety roadmap , 2015 .

[21]  Lang Tran,et al.  Comprehensive In Vitro Toxicity Testing of a Panel of Representative Oxide Nanomaterials: First Steps towards an Intelligent Testing Strategy , 2015, PloS one.

[22]  T. Kyriakides,et al.  Nanomaterials, inflammation, and tissue engineering. , 2015, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[23]  A Worth,et al.  Towards an alternative testing strategy for nanomaterials used in nanomedicine: Lessons from NanoTEST , 2015, Nanotoxicology.

[24]  M. Roman.  Toxicity of Cellulose Nanocrystals: A Review , 2015 .

[25]  Burt H Kroes,et al.  The legal framework governing the quality of (traditional) herbal medicinal products in the European Union. , 2014, Journal of ethnopharmacology.

[26]  S. Leonard,et al.  Lung biodurability and free radical production of cellulose nanomaterials , 2014, Inhalation toxicology.

[27]  E. J. Foster,et al.  An in vitro testing strategy towards mimicking the inhalation of high aspect ratio nanoparticles , 2014, Particle and Fibre Toxicology.

[28]  Eugenia Valsami-Jones,et al.  A strategy for grouping of nanomaterials based on key physico-chemical descriptors as a basis for safer-by-design NMs , 2014 .

[29]  E. J. Foster,et al.  Comparison of the properties of cellulose nanocrystals and cellulose nanofibrils isolated from bacteria, tunicate, and wood processed using acid, enzymatic, mechanical, and oxidative methods. , 2014, ACS applied materials & interfaces.

[30]  Hedwig M Braakhuis,et al.  Physicochemical characteristics of nanomaterials that affect pulmonary inflammation , 2014, Particle and Fibre Toxicology.

[31]  Lang Tran,et al.  ITS-NANO - Prioritising nanosafety research to develop a stakeholder driven intelligent testing strategy , 2014, Particle and Fibre Toxicology.

[32]  K. Schwirn,et al.  Why are nanomaterials different and how can they be appropriately regulated under REACH? , 2014, Environmental Sciences Europe.

[33]  Nianqiang Wu,et al.  Interlaboratory Evaluation of in Vitro Cytotoxicity and Inflammatory Responses to Engineered Nanomaterials: The NIEHS Nano GO Consortium , 2013, Environmental health perspectives.

[34]  Lang Tran,et al.  The biologically effective dose in inhalation nanotoxicology. , 2013, Accounts of chemical research.

[35]  Ramani Narayan,et al.  Biobased & biodegradable plastics: Rationale, drivers, and technology exemplars , 2012 .

[36]  K. Donaldson,et al.  Inhaled nanoparticles and lung cancer - what we can learn from conventional particle toxicology. , 2012, Swiss medical weekly.

[37]  G. Jenkins,et al.  In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines , 2012, Mutation research.

[38]  Jari Vartiainen,et al.  Health and environmental safety aspects of friction grinding and spray drying of microfibrillated cellulose , 2011 .

[39]  Ken Donaldson,et al.  Nanotoxicology: new insights into nanotubes. , 2009, Nature nanotechnology.

[40]  T. Webster,et al.  Nanotechnology and nanomaterials: Promises for improved tissue regeneration , 2009 .

[41]  H. Norppa,et al.  Genotoxic and inflammatory effects of nanofibrillated cellulose in murine lungs , 2017, Mutagenesis.

[42]  R. Berry,et al.  Commercialization of Cellulose Nanocrystal (NCC™) Production , 2014 .

[43]  Zuang Valerie,et al.  Alternative methods for regulatory toxicology – a state-of-the-art review , 2014 .

[44]  H. Lindberg,et al.  Nanomaterials and Human Health , 2014 .

[45]  木村 良晴.  Bio-based polymers , 2013 .

[46]  Guidance on information requirements and chemical safety assessment , 2008 .

[47]  COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ( CHMP ) GUIDELINE ON CONDUCT OF PHARMACOVIGILANCE FOR MEDICINES USED BY THE PAEDIATRIC POPULATION , 2007 .

[48]  C. Sattler,et al.  European Union Regulation Compliance Statement Registration, Evaluation, Authorization and restriction of Chemicals (REACH) , 1991 .